Medtronic touts cost, treatment data on CRT devices

Medtronic (NYSE:MDT) today touted data showing that a pair of algorithms improved treatment and lowered costs for patients treated with its cardiac resynchronization therapy devices. The Fridley, Minn.-based medical device giant said its AdaptivCRT and EffectiveCRT algorithms lowered costs and improved therapy delivery in heart failure patients with atrial fibrillation. Results from 1 of 3 analyses presented at the European Heart Rhythm Assn. Europace Cardiostim conference in Vienna this week showed that the AdaptivCRT program cut the lifetime cost of treatment by an average of €1,055 (about $1,174) in 3 European countries: With AdaptivCRT Without AdaptivCRT Difference Italy €28,113.00 €29,215.16 €1,102.16 Spain €29,618.89 €30,833.93 €1,215.04 U.K. €29,425.37 €30,273.19 €847.82 The study also showed that the algorithm extends life expectancy by an average of 4 months, Medtronic said. A 2nd study used data from the CRTee study to show that the EffectivCRT program improved left ventricular pacing by 19% compared to devices without the technology. A 3rd analysis of Medtronic’s CRT-defibrillators showed “a highly significant increase” in projected device longevity of up to 9 years for the Claria and Amplia devices and 8.1 years for the  Viva XT CRT-Ds. “These analyses reinforce Medtronic’s leadership in providing treatments and solutions that not only improve patient outcomes and CRT delivery, but also dramaticall...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiovascular Clinical Trials Cardiac Rhythm Management Medtronic Source Type: news